Introduction: Why the Report Now Feels So Strange
Something odd happens when you return to the Beyond Therapy report in 2026. The document still looks serious. It is carefully constructed, philosophically ambitious, and in places genuinely insightful. The council that produced it included some of the sharpest public intellectuals in the United States. And yet the report now produces a particular kind of retrospective unease: the feeling of encountering a world that has closed.
That feeling is worth pausing over, because it is itself analytically significant. The report does not feel dated in the way that naive or poorly argued documents feel dated. It feels dated in the way that confident documents from recently closed recursive worlds feel dated: the confidence remains visible, but the world that authorized it has moved on. The report still performs its certainties, but the recursive loop that made those certainties feel natural has, in the intervening years, completed. We are now in the metabolic reconstruction window for this document. Twenty-three years is close enough that the debates it participated in are within living memory, close enough that we can still feel the texture of the anxieties it expressed. But it is also far enough that the symbolic formation it inhabited has stabilized into something reconstructible from the outside. The loops have closed. What was once the horizon of a civilizational question is now an artifact.
Living Value Theory describes this temporal structure precisely. Events and documents from roughly ten to twenty-five years ago occupy what might be called the optimal reconstruction zone: the period in which retrospective distance has combined with the embodied presence of those who lived through the situation to produce the richest conditions for mesocosmic understanding. The people who read Beyond Therapy when it appeared, who wrote about it, who argued with it in the pages of bioethics journals, are still alive. The institutional world it inhabited is still partially continuous with ours. And yet the recursive feedback loops that constituted that world as a living controversy have completed their work. What was once the inside of a debate is now its archaeological surface.
The present article reads Beyond Therapy from that position. Its argument is not that the report was intellectually dishonest, religiously motivated, or politically cynical, though critics made all of those charges and some had merit. The argument is subtler and, I think, more interesting. The report failed not because it asked moral questions about biotechnology but because it accepted, with excessive confidence, a symbolic fantasy of biotechnology as if it were already a verified mesocosmic reality. Its deepest error was not conservatism, nostalgia, or religiosity. It was ontological overconfidence: it moralized projected transformations before establishing whether those transformations had actually occurred in the lived coordination of real people.
The report is therefore best read, from the vantage point of 2026, as a high-water mark of expert culture: a moment when elite bioethics still believed it could pronounce on childhood, happiness, authenticity, the soul, social order, and human nature from above the mesocosms it barely understood. That belief has since fractured, for reasons that the report itself helps us understand.
I. The Metabolic Reconstruction Window and the Closed World of 2003
Before turning to the report's contents, it is worth dwelling on why 2026 is an unusually good moment to read it. The observation is not merely rhetorical. Living Value Theory proposes that the reconstructibility of past events is structured along two distinct axes: temporal depth and mediational differential preservation. The relevant point here concerns the temporal axis.
Reconstruction of very recent events is complicated by the fact that the people who participated in them are still inside the recursive processes they are participating in. Their interpretations remain part of what the situation is still becoming. The patterns that will eventually be visible have not yet stabilized. At the other extreme, events from the deep past lose the metabolic living memory that enriches reconstruction: the felt, embodied, relational knowledge that only participants can supply.
Between approximately ten and twenty-five years after an event, a different situation obtains. The recursive loops have closed. What happened has a determinate shape no longer being constituted by ongoing participation. The patterns that were opaque from within have become visible from without. And crucially, the people who lived through the events are still alive, still capable of comparing accounts with each other and with the documentary record, of recognizing connections they could not see while inside the situation. This is the zone of metabolic living memory, where retrospective distance combines with embodied presence to produce the richest conditions for mesocosmic reconstruction.
The Beyond Therapy report was published in October 2003. We are now twenty-three years later, at the outer edge of the optimal reconstruction zone. This positioning matters for the article's argument. What follows is not a critique written from inside the ongoing debate that the report participated in, but a reconstruction written from the position of someone who can see the recursive world the report inhabited as a closed formation. The anxieties the report expressed, the symbolic vocabulary it deployed, the institutional authority it claimed, the pharmacological landscape it described: all of these are now reconstructible in ways they were not during the years when the controversy was still live.
What has the reconstruction revealed? Most strikingly, it has revealed that the report's central object was considerably less stable than the report assumed. The pharmacological landscape that the council moralized about has not resolved into the form the report projected. The confident claims of neuroscience and psychiatry that surrounded the report's publication have been substantially complicated in the intervening years. The great therapeutic promises of SSRIs, stimulants, memory-modulating agents, and the genetic technologies that the report placed at the center of civilizational drama have mostly not descended into lived coordination in the ways predicted. The report mistook a pharmacological mirage for an ontological revolution.
II. The Report as Monument of Expert Culture
The President's Council on Bioethics was established by executive order in November 2001. Its membership included philosophers, physicians, legal scholars, scientists, political theorists, and public intellectuals of considerable distinction. Leon Kass, who chaired the council during the period when Beyond Therapy was produced, was a rigorous and serious thinker whose philosophical anthropology drew deeply on Aristotle, Hans Jonas, and Leon Strauss. The council's other members included Michael Sandel, Francis Fukuyama, Mary Ann Glendon, and James Q. Wilson, among others. Whatever political objections were later raised about the council's composition and conduct, the intellectual ambition of Beyond Therapy is not in doubt.
What is striking, in retrospect, is the form the report takes. It is not a technical regulatory document. It is not a risk assessment or a policy brief. It is a civilizational meditation. Its organizing structure asks what biotechnology means for better children, superior performance, ageless bodies, and happy souls, before concluding with general reflections on biotechnology and the pursuit of happiness in American society. The report's letter of transmittal to the president frames biotechnology as a domain in which humanity might soon be confronted with powers that call into question what it means to be human. The human being, Kass writes, must be seen as a creature in-between, neither god nor beast, neither dumb body nor disembodied soul, but as a puzzling, upward-pointing unity of psyche and soma whose precise limitations are the source of its loftiest aspirations.
This is a serious philosophical claim with a long pedigree. And it is precisely the problem. The report does not merely evaluate biomedical risk. It converts emerging technologies into a national moral anthropology. It speaks for the human being in general, for the meaning of childhood, for what happiness truly requires, for the dignity of achievement, for the soul's proper relationship to its own alteration. This conversion is where the report's deepest error begins.
In the early 2000s, a presidential council could still plausibly imagine itself authorized to perform this translation. The composition of the council itself enacted an older model of expert authority: eminent minds gathered to interpret the meaning of the future for the nation. Since 2003, that kind of authority has fractured. Psychiatry's pharmaceutical confidence has weakened substantially. Antidepressant and stimulant claims have become more contested, not less. Patient and activist communities have grown louder and harder to dismiss. Pharmaceutical industry influence on clinical research and regulatory approval has been more widely documented. Social media has made top-down moral synthesis nearly impossible. The expert culture that the council represented was not wrong to exist, but it existed at a moment of peak symbolic authority that has not been regained.
The report is therefore not only a bioethical document. It is an artifact of a disappearing expert regime. Its power came from its ability to convert uncertain biomedical developments into civilizational questions. But that same conversion is where its analytical failure begins.
III. Pharmacological Symbolic Overreach: The Missing Mesocosmic Question
Before asking whether a technology is ethically acceptable, one must ask what the technology actually does. This sounds embarrassingly obvious. But it was not treated as foundational by the council, and the failure to treat it as foundational shaped everything that followed.
The report's discussion of Ritalin and stimulant use in children provides the clearest illustration. The chapter on Better Children devotes considerable attention to the pharmacological management of childhood behavior, raising serious and probing questions about agency, effort, social control, authentic achievement, and the relationship between drug-induced compliance and genuine self-mastery. The council worries that behavior-modifying drugs circumvent the learning process that produces character, and quotes approvingly a council member's remark that drugs for behavioral control amount to anabolic steroids for the soul. The discussion of performance enhancement extends this concern: artificial agents, the report argues, separate achievement from the effort of achieving, threatening both the integrity of individual performance and the dignity of the activities in which performance takes place.
These are not trivial concerns. But they rest on an assumption that is never adequately examined: that stimulant drugs were reliably producing the effects that would make the moral questions urgent. The report moves with considerable speed from the observation that stimulants alter certain measurable behavioral states to the conclusion that they pose questions about the soul, authentic achievement, and human dignity. The crucial intermediate question is skipped. What exactly do these drugs do in the lived coordination of the children who take them? Do they produce transformed selves, or do they produce altered classroom compliance? Do the effects persist across time, across settings, across developmental transitions? Do they descend into the lived coordination of the child's relationships, dwelling, embodied experience, and self-understanding, or do they remain, as so much psychiatric pharmacology remains, an intervention that changes certain measurable proxies while leaving the mesocosm largely intact?
Living Value Theory proposes the concept of pharmacological symbolic overreach to describe what happens when unstable, partial, context-dependent drug effects are converted into sweeping symbolic claims about authenticity, agency, happiness, enhancement, or human nature. The concept is meant to capture a specific recursive-level error: the movement from a biochemical perturbation to an ontological claim about the person, without securing the intermediate evidence that the perturbation has actually reorganized lived coordination.
A biochemical perturbation is not yet a mesocosmic transformation. A clinical effect is not yet a new ontology of the person. A marketed drug category is not yet a stable form of life. These distinctions were available to the council in principle, but they were not treated as analytically prior to the moral questions. Instead, the report accepted the symbolic inflation of psychiatry and pharmaceutical modernity at something close to face value, and then proceeded to moralize the inflated claims.
The pattern is visible throughout the report. The discussion of SSRIs and mood-brightening moves rapidly from the observation that drugs can alter felt affect to questions about whether pharmacologically induced happiness is authentic, whether it represents the real loves and attachments essential to true flourishing, whether it constitutes a form of self-alienation. The letter of transmittal puts the anxiety directly: we want to be happy, it says, but not because of a drug that gives us happy feelings without the real loves, attachments, and achievements that are essential for true human flourishing. The concern is philosophically serious. But it presupposes that SSRIs were reliably delivering the kind of hedonic transformation that would make the question pressing. The evidence for that presupposition was, in 2003, considerably weaker than the symbolic surrounding of the drugs suggested. It has become weaker still in the years since.
The council debated whether stimulants were remaking childhood before establishing what kind of childhood coordination the drugs actually changed. It debated whether antidepressants threatened authentic happiness before establishing whether they reliably produced happiness, insight, transformation, or even durable mood improvement in the ways the discourse assumed. It debated biotechnology as a new power over the soul while relying heavily on the symbolic inflation of psychiatry and pharmaceutical modernity as its evidentiary base.
The report did not misunderstand enhancement because it lacked ethics. It misunderstand enhancement because it lacked mesocosmic pharmacology: the systematic study of what a drug actually does in lived coordination, not merely in receptor binding or clinical trial endpoints, but in the real recursive life of persons, families, schools, clinics, and communities across time.
IV. From Drug to Civilizational Drama
The report's escalatory structure is worth tracing carefully, because it is not accidental. The movement from pharmacological intervention to civilizational drama follows a consistent logic: a drug or technology is identified; its claimed effects are accepted; those effects are placed inside a larger moral theater; the moral theater is connected to questions of human nature, dignity, and the good life. The escalation is not presented as escalation. It presents itself as the natural unfolding of what is genuinely at stake.
A stimulant becomes a question of childhood and social control. An SSRI becomes a question of the soul. Mood alteration becomes a question of living truly. Performance enhancement becomes a question of the dignity of human activity. Memory modulation becomes a question of personal identity and the meaning of the past. Each move follows from the previous one with apparent necessity. By the time the report reaches its conclusion, individual pharmacological interventions have been placed inside a narrative about the human being's relationship to its own nature, its aspirations, its limitations, and its proper relationship to technological transformation.
Living Value Theory calls this ascent pharmacological symbolic overreach, and it is important to be precise about why the overreach is an error. The problem is not that technologies cannot become civilizational. Technologies can and do become civilizational. The problem is that the ascent must be justified at each step by showing how the intervention actually reorganizes mesocosmic life. The report instead assumes the ascent. It treats the claimed civilizational significance of psychopharmacology as if it were an established fact about what the drugs were doing in the world, rather than a symbolic formation about what the drugs were imagined to be doing.
The symbolic recursion around these drugs vastly exceeded the verified mesocosmic power of the drugs themselves. This is why the report now feels inflated. Its moral imagination was not too large in itself. Bioethics should have a moral imagination large enough to address genuinely civilizational transformations. The problem is that the moral imagination floated above insufficiently verified effects, spinning out anxieties whose grandeur was disproportionate to what the drugs were actually accomplishing in the lives of children, patients, athletes, and families.
What is striking, from the vantage point of 2026, is how much the report's civilizational drama was co-constituted by the cultural moment it inhabited. The late 1990s and early 2000s saw the confluence of several powerful symbolic formations: the Prozac revolution and its accompanying literature, the Ritalin controversy and its media amplification, the Human Genome Project and its promises of biological mastery, the cultural ubiquity of enhancement discourse, and the backlash literature that ran from Peter Kramer through Andrew Solomon to the emerging critique of pharmaceutical culture. The report did not merely observe this field. It participated in it. Its categories were part of the recursive situation: enhancement, happy souls, biotechnology, giftedness, mastery, authentic flourishing. The report's confidence was not independent of the symbolic atmosphere it shared with its object.
Now that atmosphere has thinned. The Prozac revolution has been substantially revisited. The clinical consensus around SSRI efficacy has narrowed and complicated. The stimulant controversy has moved through cycles of alarm and normalization without resolving into the form either critics or advocates predicted. The genetic enhancement futures that the report treated as imminent have remained, twenty-three years later, largely futures. The civilizational drama the report inhabited has not dissolved, but its recursive grip has weakened. What once appeared as a profound moral horizon appears, from outside the loop, as a historically specific symbolic formation in which real pharmacological uncertainties were consistently inflated into civilizational stakes.
V. The Therapy/Enhancement Binary and the LVT Alternative
The report is admirably self-critical about its own central distinction. It explicitly acknowledges that the therapy/enhancement binary is inadequate for moral analysis. The distinction is described as a useful shorthand but finally insufficient, because therapy and enhancement are overlapping categories, because health and normality are difficult to define especially in behavioral and psychic life, and because moral questions must be addressed directly rather than settled by labels. This is one of the report's stronger analytical moments.
But having performed this critique, the report does not follow through on its implications. It abandons one binary only to install a cluster of others. Natural and artificial, given and made, authentic and inauthentic, real happiness and pharmacological happiness, genuine achievement and cheap achievement: these distinctions do the moral work that the therapy/enhancement distinction was meant to do, but they carry the same problem. They are not grounded in actual mesocosmic fit. They are grounded in a prior moral anthropology that takes certain forms of human striving and limitation as normatively constitutive of the good life.
The key question should not be whether an intervention is therapy or enhancement. The key question should be whether an intervention makes this person's life better in their actual coordination across embodiment, relationships, dwelling, material conditions, and symbolic self-understanding. This reframing sounds deceptively simple, but it has significant analytical consequences.
A stimulant may be harmful symbolic compliance in one child, useful temporary scaffolding in another, school-system substitution in a third, parental relief in a fourth, and diagnostic capture in a fifth. These are not variations on a single moral case. They are different mesocosmic situations that require different analyses. The report consistently treats variations of this kind as if they could be subsumed under a single moral frame derived from abstract claims about human nature. An antidepressant may restore life to one person, numb another, prove irrelevant to a third, function as symbolic reassurance in a fourth, or become metabolically intolerable in a fifth. The morally relevant question in each case is not whether the intervention is enhancement or therapy but whether it produces mesocosmic fit: whether it actually improves the coordination of a life across its mediations, and for whom, under what conditions, at what cost.
This alternative does not dissolve the moral questions the report raises. It relocates them. Instead of beginning with abstract claims about human nature and human dignity, it begins with the empirical question of what the intervention actually does in actual lives. The moral analysis then proceeds from that empirical base, rather than floating above it on the strength of symbolic projection. The questions about authenticity, agency, and the dignity of achievement are not abandoned. They become askable in a more precise form: does this intervention, in this person's actual world, support or undermine their capacity for the forms of self-understanding and self-direction that give life its felt value? That is a harder question than the report's framework allows, but it is the right question.
VI. The Protestant-Moral Frame as a Closed Loop
There is a further layer to the report's symbolic formation that has become newly visible from 2026, and that is worth examining as itself an example of a closed recursive world. The report's anxieties about enhancement are organized not merely by a philosophical anthropology but by a specific moral grammar that was, in the early 2000s, so pervasive as to appear natural: a grammar of inner authenticity, earned achievement, proper suffering, and deep suspicion of externally induced states.
The report repeatedly worries about achievements or happiness gained without the proper path of effort, attachment, suffering, striving, or acceptance. The letter of transmittal contrasts genuine flourishing, rooted in real loves and real achievements, with pharmacologically induced contentment. The chapter on better children worries that drugs rob children of the edifying features of effort and teach them that behavioral control comes from a bottle. The chapter on superior performance worries that enhancement separates achievement from the effort of achieving. The chapter on happy souls worries that mood-brightening produces easy contentment without the genuine attachments, appropriate discontent, and moral struggle that make happiness real. Throughout the report, the same structure recurs: something obtained through effort, suffering, and striving is real; something obtained through pharmacological shortcut is not.
What is striking from the present vantage point is how entirely this moral grammar has aged. The authenticity anxiety the report inhabits, the sense that genuine selfhood requires struggle, that pharmacological mediation of experience threatens something essential about what it means to earn one's own states, was in 2003 so culturally dominant as to seem like common sense. It shaped mainstream bioethical debate, it organized popular writing about Prozac and Ritalin, it structured the terms in which enhancement was contested across the political spectrum from left critics of medicalization to conservative critics of hubris.
From 2026, this moral grammar looks like what it was: a historically specific formation, deeply shaped by Protestant and broadly American cultural assumptions about the relationship between inner authenticity, earned achievement, and proper suffering, that had been absorbed so thoroughly into the mainstream of educated discourse that it no longer registered as culturally specific. It felt like anthropology. It was, in significant part, local moral history.
This is not a straightforwardly political observation. The report is not crude. It understands that consumerism, pharmaceutical advertising, and the manufactured desire for easy solutions can genuinely narrow human life. These are real concerns. But the moral vocabulary in which they are expressed, the language of the genuine versus the pharmacological, the earned versus the assisted, the real versus the drug-induced, now reads as the product of a particular cultural moment rather than as universal anthropology. The claim that happiness requires real loves and attachments is not wrong. The claim that pharmacological mood states are categorically incapable of supporting such loves and attachments is a symbolic assertion, not an empirical finding.
The Protestant-moral frame is therefore itself an example of what the past/future asymmetry predicts: a recently closed recursive world that is now reconstructible from outside its own terms. In 2003, this frame was the water the report swam in. In 2026, it is visible as a formation, which means it can be analyzed, historicized, and placed in relation to the mesocosmic evidence about what pharmacological interventions actually do in actual lives. The frame has not been refuted so much as decoupled from its natural appearing status. It now looks like what it always was: one historically situated moral grammar among possible others, rather than the natural expression of what human flourishing requires.
VII. Expert Culture at its High Watermark
Beyond the report's specific arguments, it is worth reflecting on what kind of epistemic authority the report assumed, and why that assumption now reads as historically specific.
The President's Council on Bioethics was established to advise on bioethical issues emerging from biomedical science and technology. Its reports were public documents aimed at a national audience. They were intended to advance the nation's awareness and understanding of critical bioethical issues and to bring them beyond the narrow circle of bioethics professionals into the larger public arena. This ambition was not merely institutional self-promotion. It reflected a genuine belief that expert synthesis of moral, scientific, and philosophical knowledge could and should shape public deliberation about emerging technologies.
That belief presupposed several things that no longer hold. It presupposed that experts could speak for the nation. It presupposed that moral philosophers and legal scholars could interpret biotechnology for ordinary life. It presupposed that psychiatrists and neuroscientists could define childhood, happiness, and authentic selfhood in terms that deserved general authority. It presupposed that a national council could synthesize science, morality, policy, and civilizational significance in a single document without that synthesis being instantly contested, fragmented, or absorbed into partisan debate. None of these presuppositions survives contact with the world as it now exists.
The report's confidence was not merely intellectual. It was institutional: the confidence of an expert culture still authorized to speak about mesocosms it had not entered. The council spoke at considerable length and with considerable authority about children in classrooms, about families navigating medicated selves, about depressed patients and their relationship to their own moods, about athletes and the dignity of their striving, about American happiness and its proper foundations. But its mode of knowledge was overwhelmingly top-down symbolic interpretation. It did not study what stimulants actually did in the households of the children who took them. It did not investigate what SSRIs actually produced in the self-understanding of the patients who used them. It did not examine what performance enhancement meant to athletes in their actual practices across time. It began with the symbolic level and projected downward.
This is the most historically specific feature of the report, and the one that is hardest to recapture from inside 2026. The expert culture the report represents was still, in 2003, sufficiently intact that this kind of top-down symbolic interpretation could present itself as national moral synthesis. It could claim to be speaking about biotechnology and the pursuit of happiness without extensive investigation of what the relevant technologies were actually producing in the lives of the people who used them. That authority has since eroded, from multiple directions simultaneously. It has eroded through the fracturing of pharmaceutical confidence. It has eroded through the proliferation of patient voices, activist communities, and first-person accounts that have contested expert frameworks from below. It has eroded through the broader fragmentation of institutional authority that has characterized the past two decades in American public life.
The report now reads, in this light, as a monument: a document in which expert culture reached its highest register of civilizational pronouncement at precisely the moment when the conditions for that pronouncement were beginning to dissolve. It is, as archaeology sometimes is, most instructive precisely where it is most confident.
VIII. What the Report Got Right
The article would be incomplete, and less interesting, if it were only a critique. Beyond Therapy got several things genuinely right, and acknowledging them is not merely a rhetorical courtesy. It is analytically necessary, because the report's failures are failures of intelligent work, and intelligent failures are more illuminating than simple errors.
The report saw, with clarity, that technologies exceed the intentions of their inventors. It notes explicitly that technologies developed for therapeutic purposes acquire dual uses beyond therapy, and that the moral analysis cannot be confined to intended applications. This is a genuine insight, and one that has been repeatedly confirmed in the years since the report's publication. Stimulants prescribed for childhood ADHD became performance enhancers for adults without diagnoses. Propranolol prescribed for heart conditions became a performance aid for musicians and public speakers. The movement from therapeutic to enhancement contexts is not exceptional but structurally expected, and the report was right to insist on this.
The report also saw, again with clarity, that commerce manufactures desire. Its concluding chapter includes a serious discussion of the pharmaceutical industry's role in creating new markets by creating new anxieties, noting that direct-to-consumer advertising can stimulate desires for mood-brightening drugs where neither existed before, and that newly created desires, and the self-understanding that accompanies them, can transform the souls of a society. This is not a naive or alarmist observation. It anticipates, in broad terms, what subsequent scholarship on pharmaceuticalization and the looping effects of psychiatric categories would document in considerably more detail. The report was right that manufactured desire is a serious moral phenomenon, even if its framework for analyzing it was ultimately inadequate.
The report further saw that the therapy/enhancement distinction is an insufficient tool for moral analysis, and said so explicitly. This self-critical move is one of its strongest moments, and the honesty with which it is made deserves recognition. The report's failure, as argued above, is not that it raised the distinction but that it replaced it with a cluster of related binaries that carried the same problem in a less visible form.
Most fundamentally, the report saw that biotechnology is not merely technical but aspirational: that it cannot be understood apart from the human desires it expresses and amplifies. The structure of inquiry around better children, superior performance, ageless bodies, and happy souls is organized by the recognition that biotechnological development is not driven by neutral technical progress but by specific human longings whose moral character deserves examination. This is a genuine contribution, and the framework of analyzing technology through the lens of the aspirations it serves, rather than through a purely risk-benefit calculus, is one that remains valuable.
The report had moral sensitivity without ontological literacy. That sentence is meant as a precise diagnosis, not a dismissal. Moral sensitivity, the capacity to see that something important is at stake when technologies engage the conditions of human flourishing, is a genuine intellectual virtue and one that the report displayed. What it lacked was the capacity to track the actual recursive effects of technologies in the mesocosms of the people who used them, to ask not what the technology symbolically promised or threatened but what it actually did in the coordination of real lives. Those are complementary competencies, and the absence of the second does not negate the presence of the first.
IX. What LVT Would Have Asked Instead
Living Value Theory does not propose to replace moral bioethics with mere empirical description. The claim is not that value questions should be set aside until pharmacological effects are fully documented, which would mean deferring ethics indefinitely. The claim is that moral analysis of biotechnology should begin from mesocosmic evidence rather than from symbolic projection, and that the sequence of questions matters as much as the questions themselves.
The foundational question is: what exactly does this intervention do? Not what is promised in marketing materials, clinical trial endpoints, or popular discourse about its transformative potential, but what it reliably produces across the range of contexts in which it is used, across diverse bodies, diverse social environments, and diverse temporal scales. This question cannot be answered from the armchair, and the council's failure to take it seriously as a prior constraint on moral analysis was not inevitable. It was a choice, made possible by the confident symbolic inflation of pharmacological promise that surrounded the report's moment of production.
The second question concerns level of operation: at which recursivity level does the intervention actually work? Does it alter bodily state in ways that descend into felt experience and lived coordination? Does it alter felt experience without significantly reorganizing the social coordination of the person's life? Does it reorganize social coordination without changing the person's institutional classification, or does it primarily alter institutional categories without producing corresponding changes at the experiential and coordinative levels? These distinctions matter enormously for moral analysis, because the moral stakes of an intervention depend on what it actually changes in the recursive life of the person it affects.
A drug that reliably shifts institutional classification, in the sense that a child goes from being regarded as disruptive to being regarded as manageable, without producing corresponding changes at the levels of embodied experience, relational coordination, and self-understanding, raises very different moral questions from a drug that produces genuine changes at all of these levels simultaneously. The report's moral framework is not equipped to make this distinction, because it operates primarily at the level of symbolic analysis rather than mesocosmic investigation.
The third question, which follows from the first two, concerns who benefits from the various symbolic frames applied to an intervention. When a drug is called a treatment, who benefits from that classification? When it is called an enhancement, who benefits from the stigma that classification carries? When a condition is defined as a disorder, what institutional interests are served by that definition, and what interests are served by contesting it? The report is not naive about these questions. Its discussion of commerce and manufactured desire shows awareness that symbolic classifications are not neutral. But the analysis does not go far enough. It does not follow the interests through the full institutional ecology of pharmaceutical development, clinical prescription, school system management, insurance coverage, parental anxiety, and media amplification that actually constitutes the mesocosmic context in which these drugs operate.
The fourth question, which may be the most important, concerns what an intervention replaces. When a stimulant is used to manage a child's classroom behavior, what is it substituting for? Smaller classes, more experienced teachers, less pressured curricula, greater parental availability, more flexible institutional expectations, or genuine neurological support for a child who experiences the world in ways that standard schooling does not accommodate? These are not equivalent cases. The moral analysis of stimulant use in childhood depends critically on which of these substitution patterns is operative in a given situation, and the report's framework provides no tools for making these distinctions.
Finally, and underlying all of the above, is the question of descent: does the intervention actually change life, or does it primarily produce new narratives about life? Does it alter the felt, bodied, relational, material coordination of daily existence, or does it predominantly create new symbolic frameworks within which people understand themselves without corresponding changes in their actual living? The distinction between an intervention that descends into lived coordination and one that remains primarily an institutional and symbolic story about the self is one of the most important analytical distinctions available to a genuinely mesocosmic pharmacology. It is almost entirely absent from the report's framework.
Bioethics, on this account, should not begin with human nature in the abstract. It should begin with mesocosmic fit: with the question of whether this intervention, under these conditions, for this person, in this social world, improves or degrades the coordination of a life across its full dimensionality. This is a more demanding starting point than the abstract moral anthropology the report offers. It requires sustained empirical engagement with the actual conditions of drug use rather than symbolic analysis of what drug use represents. But it is also a more honest starting point, because it refuses to moralize transformations before verifying that they have occurred.
Conclusion: The Report as Reconstructible Artifact
Twenty-three years later, Beyond Therapy is no longer most interesting as a guide to the future of biotechnology. It is most interesting as a document of a recently closed recursive world: a world in which psychopharmacology still appeared enchanted with transformative potential, in which expert committees still spoke with national moral authority, in which the symbolic class still believed it could name the human meaning of technologies before their lived effects had been understood, and in which a specific Protestant-American grammar of authenticity and earned suffering still presented itself as universal anthropology.
Each of these features of the report's world has, in the intervening years, lost its self-evidence. The pharmaceutical enchantment has faded into a more complicated picture of partial effects, contested evidence, and institutional capture. The expert authority has fractured. The symbolic class's confidence in its own interpretive reach has been humbled by the proliferation of other voices, other frameworks, and other forms of knowledge that contest top-down synthesis. The authenticity grammar has aged into visibility as one culturally specific formation among others, rather than the natural expression of what genuine human flourishing requires.
The report's enduring value is therefore paradoxical. It does not teach us what it intended to teach, which was the moral significance of biotechnology for the human future. It teaches us something it did not intend to teach: what it looks like when expert culture moralizes a symbolic fantasy before the underlying reality has been adequately investigated. The report feared that biotechnology would remake the human being. What it actually reveals is how easily expert culture can remake uncertainty into moral certainty.
The lesson is not that bioethics should abandon moral philosophy for empirical caution, or that uncertainty should produce paralysis. The lesson is about sequence. Before moralizing a transformation of human life, first ask whether the transformation has actually occurred. Before pronouncing on the soul's relationship to its own pharmacological alteration, first ask what the pharmacological alteration is actually doing in the coordination of real souls. Before converting drug effects into civilizational drama, first establish that the effects are robust enough, pervasive enough, and mesosocially consequential enough to warrant the scale of the moral response.
The Beyond Therapy report failed this test. It did so with intelligence, seriousness, and genuine moral concern. But it failed it nonetheless, and the failure is now reconstructible with the clarity that the optimal reconstruction window provides. The loops have closed. The recursive world the report inhabited is now archaeology. What remains is the task of reading that archaeology clearly: understanding what it preserves, what it distorts, what it assumed, and what it, in its confident overreach, failed to ask.
References
- Blackburn, E. and Rowley, J. 2004. 'Reason as Our Guide.' PLoS Biology 2(4): e116.
- Ecks, S. 2022. Living Worth: Value and Values in Global Pharmaceutical Markets. Durham: Duke University Press.
- Ecks, S. 2026. 'We Can Know the Past Much Better Than the Future.' livingvaluetheory.org.
- Fukuyama, F. 2002. Our Posthuman Future: Consequences of the Biotechnology Revolution. New York: Farrar, Straus and Giroux.
- Kass, L. et al. 2003. Beyond Therapy: Biotechnology and the Pursuit of Happiness. Washington DC: President's Council on Bioethics.
- Kirsch, I. 2010. The Emperor's New Drugs: Exploding the Antidepressant Myth. New York: Basic Books.
- Kramer, P. 1993. Listening to Prozac. New York: Viking.
- Meltzer, L.A. 2008. Review of Human Dignity and Bioethics. New England Journal of Medicine 359: 660.
- Sandel, M. 2007. The Case Against Perfection: Ethics in the Age of Genetic Engineering. Cambridge: Harvard University Press.